Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis

Allergy and Asthma Proceedings

Volumn 31, Issue 2, 2010, Pages 132-140

  LaForce, Craig F ^a   Carr, Warner ^b   Tilles, Stephen A ^c   Chipps, Bradley E ^d   Storms, William ^e   Meltzer, Eli O ^f   Edwards, Michael ^g  

^a North Carolina Clinical Research   (United States)

^b Allergy & Asthma Associates of Southern California   (United States)

^c Northwest Asthma & Allergy Center   (United States)

^d Capital Allergy and Respiratory Disease Center   (United States)

^e Storms Clinical Research Institute   (United States)

^f ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^g ALCON RESEARCH LTD   (United States)

Author keywords

Allergic rhinitis; Antihistamine; Azelastine; Corticosteroid; Efficacy; Fluticasone; Nasal spray; Olopatadine; Safety

Indexed keywords

AZELASTINE; FLUTICASONE; OLOPATADINE; PATANASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HAY FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL PRURITUS; NOSE CONGESTION; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SNEEZING; TREATMENT RESPONSE;

ADMINISTRATION, INTRANASAL; ADULT; ANDROSTADIENES; DIBENZOXEPINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; MIDDLE AGED; PHTHALAZINES; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; ULCER; XEROSTOMIA;

EID: 77950808775     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2010.31.3326     Document Type: Article

References (29)

1. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122:S1-S84, 2008. (Pubitemid 352033573)
2. Blaiss MS. Allergic rhinoconjunctivitis: Burden of disease. Allergy Asthma Proc 28:393-397, 2007.
3. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108:S2-S8, 2001.
4. Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. Allergy Asthma Proc 28:10-15, 2007.
5. Greiner AN. Allergic rhinitis: Impact of the disease and considerations for management. Med Clin North Am 90:17-38, 2006. (Pubitemid 41682029)
6. Prenner BM, and Schenkel E. Allergic rhinitis: Treatment based on patient profiles. Am J Med 119:230-237, 2006. (Pubitemid 43255061)
7. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther 12: 389-400, 1996. (Pubitemid 26405743)
8. Leonardi A, and Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 25:2539-2552, 2003. (Pubitemid 37373929)
9. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 278:1252-1261, 1996.
10. Ohmori K, Hasegawa K, Tamura T, et al. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforsch 54:809-829, 2004. (Pubitemid 39657678)
11. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 88:379-397, 2002. (Pubitemid 34516564)
12. Ratner PH, Hampel FC, Amar NJ, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar. Ann Allergy Asthma Immunol 95:474-479, 2005. (Pubitemid 41688510)
13. Meltzer EO, Hampel FC, Ratner PH, et al. Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 95: 600-606, 2005. (Pubitemid 43010489)
14. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 28:716-723, 2007.
15. Patel D, Brubaker M, Garadi R, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: Olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 28:592-599, 2007.
16. Patel P, Roland PS, Marple BF, et al. An assessment of the onset and duration of action of olopatadine nasal spray. Otolaryngol Head Neck Surg 137:918-924, 2007. (Pubitemid 350117069)
17. Kaliner MA. Azelastine and olopatadine in the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 103:373-380, 2009.
18. Berger WE, and White MV, and The Rhinitis Study Group. Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine. Ann Allergy Asthma Immunol 91:205-211, 2003.
19. LaForce CF, Corren J, Wheeler WJ, et al. Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine. Ann Allergy Asthma Immunol 93:154-159, 2004. (Pubitemid 39128495)
20. Shah SR, Nayak A, Ratner P, et al. Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: A phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther 31:99-107, 2009.
21. Par Pharmaceutical. Fluticasone propionate nasal spray, 50 mcg, package insert. Woodcliff Lake, NJ; 2008.
22. Barnes ML, Ward JH, Fardon TC, et al. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 36:676-684, 2006.
23. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 34:259-267, 2004. (Pubitemid 38315263)
24. Carr WW, Nelson MR, and Hadley JA. Managing rhinitis: Strategies for improved patient outcomes. Allergy Asthma Proc 29:349-357, 2008.
25. Ratner PH, Hampel F, Van Bavel J, et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 100: 74-81, 2008.
26. Lee C, and Corren J. Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis. Expert Opin Pharmacother 8:701-709, 2007. (Pubitemid 46547022)
27. MedPointe Pharmaceuticals, MedPointe Healthcare, Inc. Astelin package insert. Somerset, NJ; 2006.
28. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 62:1071-1077, 2007. (Pubitemid 47220982)
29. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 131: 225-231, 2004. (Pubitemid 39208700)